Manitex International Reports Fourth Quarter and Full-Year 2022 Results
Delivers strong year-over-year growth in revenue, Adjusted EBITDA and profitability Introduces “Elevating Excellence” value creation…
Month: March 2023
OrbusNeich Announces First Annual Results After Listing, Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million
HONG KONG, Mar 8, 2023 – (ACN Newswire) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich”…
Quamnet Outstanding Enterprise Awards 2022 Announces the Awarded Enterprises
HONG KONG, Mar 8, 2023 – (ACN Newswire) – Quamnet Outstanding Enterprise Awards 2022 announced…
Epishine and Atmosic Create New Possibilities for Low-Power Electronics
Swedish company Epishine announces a partnership with US-based Atmosic Technologies. The combination of Epishine’s indoor…
Surge in Cloud Adoption Means a Greater Data Attack Surface for Healthcare and Financial Services, Finds Blancco Report
Organizations in both industries are falling short when addressing new challenges to protect data in…
Enterprise Software M&A Achieves Record Growth, Despite Shrink In Private Equity Investment, Says Hampleton Partners’ Report
London, UK – 8 March 2023. The latest Enterprise Software M&A report from Hampleton Partners,…
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
Sponsor of Gastro Update 2023, 2-day scientific and training events for gastroenterology professionals Patient Education…
Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market
Tokyo, Japan and Cambridge, UK, 8 March 2023 – Sosei Group Corporation (“the Company”; TSE:…
Antev Receives US FDA Guidance on Teverelix® Phase 3 Trial Design for Treating Advanced Prostate Cancer Patients with Increased Cardiovascular Risk
Phase 3 aims to demonstrate cardiovascular benefit of Teverelix versus GnRH agonists. Up to 30%…
Notice to convene Extraordinary General Meeting
MARCH 8, 2023 – ANNOUNCEMENT NO. 4 An Extraordinary General Meeting of Chr. Hansen Holding…
Invitation to an extraordinary shareholders’ meeting of Novozymes A/S
To the shareholders of NovozymesThe Board of Directors is pleased to invite you to an…
Publication of exemption document in relation to the proposed combination of Chr. Hansen and Novozymes, confirmation of outlook for 2022/23 and proposed candidates to the Board of Directors of the combined company
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN…
Publication of exemption document in relation to the proposed combination of Novozymes and Chr. Hansen, confirmation of outlook for 2023 and proposed candidates to the Board of Directors of the combined company
Please read the full announcement in the attached PDF Attachment 2023_39_Exemption_Document_and_NewCo_Board_Composition
Reliq Health Technologies, Inc. Announces 40 New Skilled Nursing Facility Clients in California, Florida and Pennsylvania
HAMILTON, Ontario, March 08, 2023 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF…
Pax8 Partners with Adobe to Offer Digital Media Solutions to MSPs Across Europe
RIGA, Latvia, March 08, 2023 (GLOBE NEWSWIRE) — Pax8, the leading cloud commerce marketplace, has…
Carlisle, UK Content Keyword Optimisation Strategies Expanded by ClimbHigh SEO
ClimbHigh SEO, a full-service digital marketing agency with a focus on SEO services, have refined…
Rivian Automotive, Inc. Prices $1.3 Billion Green Convertible Senior Notes Offering
IRVINE, Calif.–(BUSINESS WIRE)–Rivian Automotive, Inc. (Nasdaq: RIVN) (“Rivian”) today announced the pricing of its offering…
Juniper Networks® Partners with Shaare Zedek Medical Center to Accelerate Digital Transformation with Automated Data Center
Data center operations reimagined to assure the availability of clinical and administrative applications SUNNYVALE, Calif.–(BUSINESS…
CROSSTEC Group (3893.HK) Appoints Chief Executive Officer
HONG KONG, Mar 8, 2023 – (ACN Newswire) – CROSSTEC Group Holdings Limited (HKEX stock…
FDA Accepts Mesoblast’s Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023
If Approved, Remestemcel-L will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and…